Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.
Highest usefulness score first. Studies without a score come last.
-
Plans for the next phase of the ADNI project include maintaining longitudinal follow-up of the normal and mild cognitive impairment cohorts, augmenting specific clinical cohorts, and incorporating novel computerized cognitive assessments and patient-reported outcomes.
-
With data collected over 20 years, this study demonstrated greater likelihood of cognitive impairment in individuals with repeated high or increasing IL-6.
-
Alzheimer's disease (AD) affects approximately 35 million people worldwide.
-
Currently, insufficient evidence exists to draw firm conclusions on the association of any modifiable factors with risk of AD.
-
Risk of overall dementia and its subtypes was not associated with MetS or any MetS component in participants younger than 75.
-
The findings demonstrate a twofold increase in the proportion with cognitive impairment in subjects with early, untreated Parkinson disease (PD) compared to controls.
-
Changing instructions while maintaining the same cognitive and motor tasks on WWT in older adults result in task prioritization effects.
-
We developed prediction rules to guide the clinical diagnosis of Alzheimer's disease (AD) in two community-based cohort studies (the Religious Orders Study and the Rush Memory and Aging Project).
-
The volume of the hippocampal formation predicted performance on most acquisition and recall measures across the spectrum of normal aging and AD.
-
We conducted a case-control study in 100 cases who had Alzheimer's-type dementia and 100 age-, sex-, and education-matched, nondemented controls to evaluate the hypothesis that hearing impairment contributes to cognitive dysfunction in older adults.
-
In response to correspondence from Cognivue, Inc. regarding our publication (Jannati et al., 2025), we clarify that our analysis employed a rigorous paired-sample design using the same 930 participants from the Bio-Hermes-001 study for both the Digital Clock and Recall® (DCR) and Cognivue Clarity® assessments.
-
Survivors of childhood cancer are prone to neurocognitive impairment and premature aging, raising concerns about early onset dementia.
-
54/100
BackgroundCognitive impairment significantly impacts the quality of life in patients with neurodegenerative disorders, including Huntington's disease (HD), Parkinson's disease (PD), and Alzheimer's disease (AD).ObjectiveThis study aims to assess the utility of MemTrax, a contemporary digital continuous recognition task platform originally developed for AD, as an effective tool for revealing cognitive and clinical motor impairments in HD and PD populations as aligned with respective disease staging.
-
54/100
Minoritized individuals had lower scores and/or greater likelihood of impairment on measures of lexical retrieval, processing speed, cognitive flexibility, and working memory but not global cognition, verbal recall, attention, and category fluency.
-
A high Pearson correlation coefficient of 0.77 (CI = 0.63-0.86) was observed between the two scores.
-
54/100
In participants with impaired cognition, baseline sleep apnea was related to better baseline MoCA performance (b = 0.65, 95% confidence interval [95% CI] = [0.07, 1.23]) and less decline in GCA over time (b = 0.06, 95% CI = [0.001, 0.12]).
-
54/100
We tested if cognitive and brain reserve and maintenance explain individual differences in episodic memory and other cognitive domains from late middle to early older adulthood.
-
CR varied across five cognitive assessments and was greater in female participants, associated with longer survival, and weakly associated with educational attainment or APOE ε4 allele.
-
54/100
Baseline data predicted that 36 patients with MCI would progress to the AD clinical syndrome (ADS Progressing).
-
54/100
The main form of vitamin D in all brain regions measured was 25(OH)D3 .
-
Previous studies have explored the associations of retinal vessel calibre, measured from retinal photographs or fundus images using semi-automated computer programs, with cognitive impairment and dementia, supporting the concept that retinal blood vessels reflect microvascular changes in the brain.
-
Cognitive reserve (CR) has been introduced to explain individual differences in susceptibility to cognitive or functional impairment in the presence of age or pathology.
-
This study aimed to investigate the interaction between weight loss (WL) and plasma amyloid-β 42/40 (Aβ 42/40), neurofilament light chain (NfL), progranulin, and their association with cognitive decline over time among older adults.
-
CVRF prevalence was 62.8% (n=150) for high cholesterol, 45.2% (n=108) for hypertension, 10.9% (n=26) for atrial fibrillation, and 7.5% (n=18) for diabetes.
-
54/100
The proportion between women and men was significantly different (68.7% [95% CI 63.9-73.4 vs 31.4%, 95% CI 26.6-36.0]).
From across this topic
9 of the 1,533 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 9. The same 9 appear here every time.
- Telomere shortening in late-life depression: A potential marker of depression severity
- A quantitative morphometric analysis of the neuronal and synaptic content of the frontal and temporal cortex in patients with Alzheimer's disease
- Hippocampal and cortical atrophy predict dementia in subcortical ischemic vascular disease
- Do the posterior midline cortices belong to the electrophysiological default-mode network?
- Structural neuroimaging as clinical predictor: A review of machine learning applications
- Estimating the age of healthy subjects from T1-weighted MRI scans using kernel methods: exploring the influence of various parameters
- An explainable multimodal framework for exploring depression-associated speech representations in Alzheimer’s disease
- Artificial Intelligence for Alzheimer’s Disease Detection Across Neuroimaging and Speech: A Reproducible Cross-Modal Secondary Analysis
- Dementia prevention and reserve against neurodegenerative disease